Please assess the completion status of the following clinical trial:

Trial Title: Response to Albuterol Delivered Through an Anti-static Valved Holding Chamber During Nocturnal Bronchospasm

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18-65 years.~* Physician diagnosis of asthma.~* FEV1 60-80% predicted during the day.~* FEV1 increases ≥ 12 % and to ≥ 80% predicted after 2- 4 puffs of albuterol HFA MDI delivered by antistatic VHC.~* No smoking in the previous year and \< 10-pack year history.~* No history of severe asthma attacks requiring ER visit or hospitalization in the previous three months.~Exclusion Criteria:~* Patient required a short course of oral steroid in the past 30 days.~* Any disease that is inadequately controlled or any medication that would worsen asthma or interact with asthma medications.~* History of viral respiratory tract infection in the 3 weeks prior to the screening visit.~* Positive pregnancy test.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Anti-static then Static for Albuterol (Type: EXPERIMENTAL): albuterol anti-static first then static chamber second.
- Static then Anti-static for Albuterol (Type: EXPERIMENTAL): static then antistatic albuterol

Based on this trial design, predict the completion outcome and termination type (if applicable).